IGM Biosciences (IGMS) Stock Price, News & Analysis

Company Overview

IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of autoimmune diseases. IGM Biosciences, Inc. has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.

Key Stats

• Today's Range: $6.76 to $7.50
• 50-Day Range: $6.90 to $17.83
• 52-Week Range: $6.17 to $22.50
• Volume: 434,862 shs
• Average Volume: 301,638 shs
• Market Capitalization: $410.30 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $17.75
• Consensus Rating: Moderate Buy

IGM Biosciences Stock Analysis - MarketRank™

IGM Biosciences scored higher than 91% of companies evaluated by MarketBeat, and ranked 105th out of 947 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

IGM Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 5 buy ratings, 2 hold ratings, and 1 sell rating.

Amount of Analyst Coverage

IGM Biosciences has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for IGM Biosciences are expected to grow in the coming year, from ($3.33) to ($2.42) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of IGM Biosciences is -1.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of IGM Biosciences is -1.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

IGM Biosciences has a P/B Ratio of 1.99. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

15.41% of the float of IGM Biosciences has been sold short.

Short Interest Ratio / Days to Cover

IGM Biosciences has a short interest ratio ("days to cover") of 8.7.

Change versus previous month

Short interest in IGM Biosciences has recently decreased by 4.93%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

IGM Biosciences does not currently pay a dividend.

Dividend Growth

IGM Biosciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.6 / 5
• Environmental Score: -1.08

Percentage of Shares Shorted

15.41% of the float of IGM Biosciences has been sold short.

Short Interest Ratio / Days to Cover

IGM Biosciences has a short interest ratio ("days to cover") of 8.7.

Change versus previous month

Short interest in IGM Biosciences has recently decreased by 4.93%, indicating that investor sentiment is improving.

News and Social Media

• Score: 1.9 / 5
• News Sentiment: 0.39

News Sentiment

IGM Biosciences has a news sentiment score of 0.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for IGM Biosciences this week, compared to 3 articles on an average week.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, IGM Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $16,808.00 in company stock.

Percentage Held by Insiders

57.00% of the stock of IGM Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

42.79% of the stock of IGM Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

IGMS Stock Analysis - Frequently Asked Questions

How have IGMS shares performed this year?

IGM Biosciences' stock was trading at $8.31 at the beginning of 2024. Since then, IGMS stock has decreased by 17.0% and is now trading at $6.90.
View the best growth stocks for 2024 here.

How were IGM Biosciences' earnings last quarter?

IGM Biosciences, Inc. (NASDAQ:IGMS) posted its earnings results on Friday, November, 8th. The company reported ($1.01) earnings per share for the quarter, missing the consensus estimate of ($0.82) by $0.19. The firm had revenue of $0.52 million for the quarter, compared to analysts' expectations of $0.23 million. IGM Biosciences had a negative trailing twelve-month return on equity of 155.42% and a negative net margin of 7,534.03%.

When did IGM Biosciences IPO?

IGM Biosciences (IGMS) raised $125 million in an initial public offering on Wednesday, September 18th 2019. The company issued 7,800,000 shares at $15.00-$17.00 per share. Jefferies, Piper Jaffray, Stifel and Guggenheim Securities acted as the underwriters for the IPO.

Who are IGM Biosciences' major shareholders?

Top institutional shareholders of IGM Biosciences include Baker BROS. Advisors LP (6.90%), State Street Corp (0.79%), Geode Capital Management LLC (0.67%) and Charles Schwab Investment Management Inc. (0.25%). Insiders that own company stock include Bros Advisors Lp Baker, Mary Beth Harler, Fred Schwarzer, Bruce Keyt, Misbah Tahir, Jakob Haldor Topsoe, Chris H Takimoto, George Gauthier, Michael D Loberg, Steven Weber and Julie Hambleton.
View institutional ownership trends.

How do I buy shares of IGM Biosciences?

Shares of IGMS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of IGM Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that IGM Biosciences investors own include American Water Works (AWK), Waste Connections (WCN), Humana (HUM), The RMR Group (RMR), DiamondRock Hospitality (DRH), AUO (AUOTY) and Voyager Therapeutics (VYGR).

Company Calendar

• Last Earnings: 11/08/2024
• Today: 12/21/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:IGMS
• CUSIP: N/A
• CIK: 1496323
• Web: igmbio.com
• Phone: 650-965-7873
• Fax: N/A
• Employees: 190
• Year Founded: 2010

Price Target and Rating

• Average Stock Price Target: $17.75
• High Stock Price Target: $27.00
• Low Stock Price Target: $9.00
• Potential Upside/Downside: +157.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 8 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($3.64)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-246,420,000.00
• Net Margins: -7,534.03%
• Pretax Margin: -7,525.74%
• Return on Equity: -155.42%
• Return on Assets: -61.04%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.22
• Quick Ratio: 5.22

Sales & Book Value

• Annual Sales: $2.92 million
• Price / Sales: 140.61
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.46 per share
• Price / Book: 1.99

Miscellaneous

• Outstanding Shares: 59,464,000
• Free Float: 25,570,000
• Market Cap: $410.30 million
• Optionable: Optionable
• Beta: 0.08